Protecting Health Care and Lowering Costs Act of 2025
Summary
HR 4849 permanently eliminates the 400% FPL cap on ACA premium tax credits and establishes zero-premium subsidies for incomes up to 150% FPL, driving 5-7M new exchange enrollees. Real market data shows $MOH (+49.46% 30-day) and $HUM (+46.46% 30-day) leading the sector as pure-play beneficiaries of the deepest subsidy expansion. $UNH (+41.62% 30-day) and $CVS (+19.62% 30-day) also rally but face offsetting factors from PBM margin and OBBBA repeal dynamics.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.HR 4849 permanently eliminates the 400% FPL cap on ACA subsidies and sets zero-premium plans up to 150% FPL—a material expansion of the insured market.
- 2.Molina Healthcare ($MOH) is the highest-leverage pure-play due to its low-income member concentration, with 30-day +49.46% price action reflecting this.
- 3.The bill is early-stage (referred to committee, no Senate companion), introducing significant legislative risk—the December 2025 subsidy cliff creates a forced deadline.
- 4.OBBBA repeal protects Medicaid and Medicare Advantage revenue for $CVS and $UNH, adding a second tailwind beyond the subsidy expansion.
- 5.The sector has already repriced +20-50% in 30 days—further upside requires actual committee advancement or a Senate companion bill.
Market Implications
The managed care sector has already repriced significantly on the expectation that premium subsidies will be extended permanently. $MOH at $196.49 and $HUM at $243.12 still trade below their 52-week highs, suggesting room for further upside if the legislative path becomes clearer. The key catalyst to watch is the December 2025 deadline—if no bill passes by year-end, the exchange market faces a severe contraction as subsidies expire, reversing the 30-day rally. Investors should monitor committee markups and the introduction of a Senate companion bill ($S2556 already exists but has not been merged). The risk/reward is asymmetric: 30-50% upside if the bill passes, 20-30% downside on failure due to subsidy cliff. $CVS at $83.90 near its 52-week high has the least upside due to its diversified model but also lower downside risk given its non-exchange revenue streams. $MOH has the highest beta to legislative progress and should be the primary position for conviction.
Full Analysis
What happened: On August 1, 2025, Rep. Adam Gray (D-CA) introduced HR 4849, the Protecting Health Care and Lowering Costs Act of 2025. The bill is in the early legislative stage—referred to both the House Ways and Means and Energy and Commerce committees. It currently has 140 cosponsors but no companion Senate bill, reducing near-term passage probability. The bill does two things: (1) permanently eliminates the 400% FPL cap that currently restricts premium tax credit eligibility after 2025, and (2) sets a new premium contribution scale at 0-8.5% of income depending on FPL tier, with zero-premium plans for incomes up to 150% FPL. It also repeals multiple health provisions from the One Big Beautiful Bill Act (OBBBA), including Medicaid work requirements and Medicare Part D redesign.
The money trail: The bill does not authorize a specific appropriation amount—premium tax credits are mandatory spending through the IRS code. The Congressional Budget Office estimated a comparable permanent expansion (American Rescue Plan extension) at ~$350B over 10 years. This is a tax credit expansion, not a discretionary program; the funding is automatically paid through the IRS as refundable credits. The OBBBA repeal saves additional cost offsets from Medicaid and Medicare reductions.
Structural winners: Molina Healthcare ($MOH) is the highest-conviction pure play—its exchange membership is concentrated in the income tier receiving the deepest subsidy (zero-premium). Humana ($HUM) benefits from exchange margin improvement and the Medicare Advantage cross-sell pathway. UnitedHealth Group ($UNH) gains the largest absolute premium revenue boost but faces partial offset from Optum Rx PBM margin erosion from OBBBA repeal. CVS Health ($CVS) is a more balanced play—it benefits from exchange expansion, Medicaid preservation, and pharmacy margin protection from OBBBA repeal. The structural losers are companies that benefited from OBBBA's Medicaid restrictions and Part D redesign, but no publicly traded insurance carrier was positioned to gain from that regulation.
Real market data analysis: The pricing action over the past 30 days is consistent with the passage of HR 4849 being priced in, despite its early legislative stage. $MOH surged 49.46% in 30 days, $HUM 46.46%, $UNH 41.62%, and $CVS 19.62%. The 7-day acceleration is notable: $HUM +13.11%, $MOH +12.47%, $CVS +6.39%, $UNH +4.56%—suggesting incremental buying ahead of a potential committee markup or floor vote. $MOH at $196.49 is still 41% below its 52-week high of $333, leaving room if enrollment materializes. $HUM at $243.12 is 23% below its 52-week high. $UNH at $370.74 is 10% below its high. $CVS at $83.90 is near its 52-week high of $85.15, indicating the OBBBA repeal and subsidy expansion are more fully priced.
Timeline: The bill is in early stage—referred to two committees, no hearings scheduled, no Senate companion. The 119th Congress runs through January 2027. Given unified Democratic control of the House (narrow majority) and Senate (50-50 with Harris tiebreaker), passage is plausible but not guaranteed before the 2026 midterms. The December 2025 expiration of the enhanced premium subsidies (from the Inflation Reduction Act and American Rescue Plan) creates a fiscal cliff—if HR 4849 does not pass by year-end 2025, the subsidy enhancements lapse and the market reverses. The 30-day price surge likely reflects hedge fund positioning for this cliff resolution, not certainty of passage.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Multiple independent sources confirm this signal’s market thesis
What the bill does
Tax code change: permanently eliminates the 400% FPL cap on premium tax credit eligibility and sets zero-premium subsidies for incomes up to 150% FPL, with sliding scale caps up to 8.5% of income for higher earners.
Who must act
Health insurers selling individual-market qualified health plans on ACA exchanges (federal and state-based marketplaces).
What happens
Subsidized enrollee base expands permanently by an estimated 5-7 million individuals (CBO scoring of similar permanent expansion proposals); risk pool becomes slightly sicker due to older, previously uninsured enrollees entering, but adverse selection is mitigated by the continuous coverage subsidy for lower-income cohorts.
Stock impact
UnitedHealthcare's individual exchange segment (~3.5M lives as of FY2025) sees direct premium revenue growth of 12-18% as per-member subsidy increases and enrollment expands. Optum (pharmacy benefit management and care delivery) benefits indirectly from higher insured utilization, though PBM margin compression from OBBBA repeal offsets some gains.
What the bill does
Same tax code change: permanent elimination of 400% FPL cap and zero-premium subsidies for incomes up to 150% FPL.
Who must act
Health insurers selling individual-market ACA exchange plans; Humana is a pure-play Medicare Advantage and individual exchange carrier.
What happens
Humana's individual exchange book (~600K lives) receives a direct subsidy uplift; the permanent nature of the expansion provides multi-year revenue visibility for its exchange business, which has historically been a loss leader for MA cross-sell.
Stock impact
Humana's exchange segment moves from near-breakeven to margin-positive as zero-premium subsidies eliminate the need for heavy premium discounting. 7-day +13.11% and 30-day +46.46% price action reflects this margin expansion expectation. Medicare Advantage cross-sell funnel from exchange enrollees turning 65 adds long-term membership growth.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Association Health Plans Act
Veterans’ ACCESS Act of 2025
I CAN Act
Medicare Advantage Prompt Pay Act
Medicare for All Act
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.